Interrogating the ubiquitin pathway to understand and treat cytokine-induced beta-cell death in type 1 diabetes
探究泛素通路以了解和治疗 1 型糖尿病中细胞因子诱导的 β 细胞死亡
基本信息
- 批准号:10278303
- 负责人:
- 金额:$ 55.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-30 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Alberta provinceApoptosisAreaAutoimmune DiabetesAutoimmune DiseasesBeta CellBindingBiologyCell DeathCell LineCell SurvivalCell physiologyCellular biologyChemicalsClinicalComplexComplications of Diabetes MellitusCytokine SignalingDevelopmentDiabetes MellitusDiabetic mouseDiseaseEquilibriumEventGene Expression ProfilingGeneticGoalsHeartHumanHypoglycemiaImmuneImmune TargetingIn VitroIndividualInflammatoryInsulinInsulin-Dependent Diabetes MellitusInterferon Type IIInterleukin-1 betaJAK2 geneKidneyLabelLeadLysineMeasurableMeasurementMediatingMethodsModelingMorbidity - disease rateMusMutateNon obeseOutcomePancreasPathway interactionsPatientsPeripheral NervesPhenotypePhosphorylationPhosphotransferasesPost-Translational Protein ProcessingProcessProteinsProteomicsRetinaRiskRoleSTAT1 geneSignal TransductionStructure of beta Cell of isletTNF geneTherapeuticTyrosineUbiquitinUbiquitinationUniversitiesactivity-based protein profilinganalogcellular targetingchemoproteomicscytokineearly detection biomarkersimprovedin vivoinnovationisletkinase inhibitorknock-downmortality riskmouse modelnovel therapeutic interventionpreservationpreventresponsescreeningsmall moleculetool
项目摘要
PROJECT SUMMARY
The loss of insulin-producing beta cells in the pancreas results in an absolute requirement for injected insulin,
causing significant risks of mortality from hypoglycemia and morbidity from diabetic complications in peripheral
nerves, the retina, the heart, and the kidney. A key goal of efforts to treat T1D is to stop this cellular attack, either
by halting the immune mis-recognition of beta cells or by protecting beta cells from cell death. However, a critical
barrier to progress in the field is a lack of complete understanding of the cellular events in the islet that contribute
to the loss of beta-cell mass. Using a phenotypic screening approach, we discovered BRD0476, a compound
that is selectively active against cytokine-mediated apoptosis. Further study of this compound revealed that it
binds the deubiquitinase USP9X to halt JAK2 and STAT1 signaling in response to IFNγ. We determined that
JAK2 can be rendered signaling incompetent by ubiquitination, and that by modulating USP9X, we can tip the
balance toward reduced JAK2 kinase activity, even in the presence of IFNγ. These results point to an emerging
role for ubiquitination in regulating beta-cell apoptosis in T1D, and suggest that a greater understanding of this
process (and its potential dysregulation) in the early stages of T1D development could lead to 1) the ability to
identify at-risk individuals, and 2) novel therapeutic strategies to preserve beta-cell mass in early-stage T1D.
Using our probe BRD0476 and chemical biology tools not previously applied to islet biology, we will improve our
understanding of the role of USP9X in beta-cell survival in vitro and in vivo through the following aims: In Aim 1,
we will characterize the mode of JAK2 inhibition by USP9X in human islets. In Aim 2, we will assess effects of
inhibiting USP9X-JAK2 (with BRD0476) on development and progression of autoimmune diabetes in a mouse
model of type 1 diabetes. In Aim 3, we will profile deubiquitinase (DUB) expression and activity in human islets
during early T1D development, using activity-based protein profiling (ABPP) and global ubiquitome
measurements. The successful outcomes of this proposal are 1) a greater understanding of mechanisms to
promote beta-cell survival in early T1D, and 2) a chemical probe to provide translational proof-of-concept. This
project will set the stage for developing a biomarker of early-stage T1D development, as well as advanced
therapeutic strategies for preventing beta-cell apoptosis in early-stage T1D, representing a potentially curative
approach.
项目摘要
胰腺中产生胰岛素的β细胞的损失导致对注射胰岛素的绝对需求,
在外周血中引起低血糖死亡和糖尿病并发症发病的显著风险
神经视网膜心脏和肾脏治疗T1 D的一个关键目标是阻止这种细胞攻击,
通过阻止β细胞的免疫错误识别或通过保护β细胞免于细胞死亡。然而,一个关键的
该领域进展的障碍是缺乏对胰岛中细胞事件的完全理解,
与β细胞团的丧失有关使用表型筛选方法,我们发现了BRD 0476,
其选择性地对精氨酸介导的细胞凋亡具有活性。对这种化合物的进一步研究表明,
结合去遍在蛋白酶USP 9 X以响应IFNγ而停止JAK 2和STAT 1信号传导。我们确定
JAK 2可以通过泛素化使其信号传导功能丧失,并且通过调节USP 9 X,我们可以使JAK 2的信号传导功能丧失。
平衡降低JAK 2激酶活性,即使在IFNγ存在下。这些结果表明,
泛素化在调节T1 D β细胞凋亡中的作用,并建议更好地理解这一点,
在T1 D发展的早期阶段的过程(及其潜在的失调)可能导致1)
鉴定处于风险中的个体,和2)在早期T1 D中保留β细胞群的新治疗策略。
使用我们的探针BRD 0476和以前未应用于胰岛生物学的化学生物学工具,我们将改进我们的
通过以下目的了解USP 9 X在体外和体内β-细胞存活中的作用:在目的1中,
我们将描述USP 9 X在人胰岛中抑制JAK 2的模式。在目标2中,我们将评估
在小鼠中抑制USP 9 X-JAK 2(与BRD 0476一起)对自身免疫性糖尿病的发展和进展的影响
1型糖尿病的发病机制在目标3中,我们将分析人胰岛中去泛素化酶(DUB)的表达和活性
在早期T1 D发展过程中,使用基于活性的蛋白质谱(ABPP)和全局泛素化
测量.这一建议的成功结果是:1)更好地理解了
促进早期T1 D中的β细胞存活,和2)提供翻译概念验证的化学探针。这
该项目将为开发早期T1 D发展的生物标志物以及高级生物标志物奠定基础。
在早期T1 D中预防β细胞凋亡的治疗策略,代表了一种潜在的治疗方法
approach.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROHIT N. KULKARNI其他文献
ROHIT N. KULKARNI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROHIT N. KULKARNI', 18)}}的其他基金
Interrogating the ubiquitin pathway to understand and treat cytokine-induced beta-cell death in type 1 diabetes
探究泛素通路以了解和治疗 1 型糖尿病中细胞因子诱导的 β 细胞死亡
- 批准号:
10477373 - 财政年份:2021
- 资助金额:
$ 55.68万 - 项目类别:
Enhanced pancreatic islet cell engraftment by treatment with serpin B1
丝氨酸蛋白酶抑制剂 B1 处理增强胰岛细胞植入
- 批准号:
10383270 - 财政年份:2021
- 资助金额:
$ 55.68万 - 项目类别:
Interplay between SerpinB1 and TLR2/TLR4 in beta cell regeneration
SerpinB1 和 TLR2/TLR4 在 β 细胞再生中的相互作用
- 批准号:
10094305 - 财政年份:2020
- 资助金额:
$ 55.68万 - 项目类别:
One-compound, one-islet: A high-throughput platform for small-molecule discovery
一种化合物,一种胰岛:用于小分子发现的高通量平台
- 批准号:
10450745 - 财政年份:2019
- 资助金额:
$ 55.68万 - 项目类别:
One-compound, one-islet: A high-throughput platform for small-molecule discovery
一种化合物,一种胰岛:用于小分子发现的高通量平台
- 批准号:
10356005 - 财政年份:2019
- 资助金额:
$ 55.68万 - 项目类别:
Interplay Between SERPINB1 and TLR2/TLR4 in Beta Cell Regeneration
SERPINB1 和 TLR2/TLR4 在 Beta 细胞再生中的相互作用
- 批准号:
10301008 - 财政年份:2018
- 资助金额:
$ 55.68万 - 项目类别:
Interplay Between SERPINB1 and TLR2/TLR4 in Beta Cell Regeneration
SERPINB1 和 TLR2/TLR4 在 Beta 细胞再生中的相互作用
- 批准号:
10378332 - 财政年份:2018
- 资助金额:
$ 55.68万 - 项目类别:
Regulation of Autoimmune Type 1 Diabetes by Serpins B1 and A1 (Alpha 1-Antitrypsin)
Serpins B1 和 A1(α 1-抗胰蛋白酶)对自身免疫性 1 型糖尿病的调节
- 批准号:
9556000 - 财政年份:2018
- 资助金额:
$ 55.68万 - 项目类别:
Interplay Between SERPINB1 and TLR2/TLR4 in Beta Cell Regeneration
SERPINB1 和 TLR2/TLR4 在 Beta 细胞再生中的相互作用
- 批准号:
10062405 - 财政年份:2018
- 资助金额:
$ 55.68万 - 项目类别:
Role of 12-lipoxygenase and 12-HETE signaling in beta-cell dysfunction
12-脂氧合酶和 12-HETE 信号在 β 细胞功能障碍中的作用
- 批准号:
10058354 - 财政年份:2015
- 资助金额:
$ 55.68万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 55.68万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 55.68万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 55.68万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 55.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 55.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 55.68万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 55.68万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 55.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 55.68万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 55.68万 - 项目类别:
Discovery Grants Program - Individual